Download PDF
Semin Plast Surg 2009; 23(2): 090-099
DOI: 10.1055/s-0029-1214161
© Thieme Medical Publishers

Systemic Antimicrobial Therapy in Osteomyelitis

Henry S. Fraimow1
  • 1University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Division of Infectious Diseases, Cooper University Hospital, Camden, New Jersey
Further Information

Publication History

Publication Date:
30 April 2009 (online)

    Permissions and Reprints

ABSTRACT

Appropriately designed antibiotic regimens are critical to the management of all stages of osteomyelitis, although goals of therapy may vary in different stages of infection. The most important consideration for antibiotic selection is spectrum of action. Route of administration by intravenous or oral route is less important than drug levels that are achievable at the site of infection. Outpatient parenteral therapy and use of oral agents has simplified delivery of long-term treatment regimens. There are few high-quality studies that compare specific treatment regimens or durations of therapy, and recommendations for drugs and duration of antibiotic therapy are based on expert opinion, case series, and extrapolations from animal models. Intravenous β-lactams are the treatment of choice for methicillin-susceptible Staphylococcus aureus, but there are also oral options available. Vancomycin has been the treatment of choice for methicillin-resistant Staphylococcus aureus osteomyelitis, but there are several newer parenteral and oral agents for treatment of methicillin-resistant Staphylococcus aureus including linezolid and daptomycin. Rifampin combined with other staphylococcal agents may increase cure rates, especially for device-associated infections. Oral fluoroquinolones and parenteral β-lactam agents can be used for treatment of gram-negative osteomyelitis, but increasing resistance has complicated management of these infections.

KEYWORDS

Osteomyelitis - Staphylococcus aureus osteomyelitis - methicillin-resistant Staphylococcus aureus - outpatient parenteral antibiotic therapy - fluoroquinolones

REFERENCES

  • 1 Lew D P, Waldvogel F A. Osteomyelitis.  Lancet. 2004;  364 369-379
    CrossrefPubMedGoogle Scholar
  • 2 Mader J T, Norden C, Nelson J D, Calandra G B. Evaluation of new antiinfective drugs for the treatment of osteomyelitis in adults.  Clin Infect Dis. 1992;  15 S155-S161
    PubMedGoogle Scholar
  • 3 Lazzarini L, Lipsky B A, Mader J T. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trails?.  Int J Infect Dis. 2005;  9 127-138
    CrossrefPubMedGoogle Scholar
  • 4 Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzoit F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections.  Lancet Infect Dis. 2001;  1 175-188
    CrossrefPubMedGoogle Scholar
  • 5 Lazzarini L, de Lalla F, Mader J T. Long bone osteomyelitis.  Curr Infect Dis Rep. 2002;  4 439-445
    CrossrefPubMedGoogle Scholar
  • 6 Rybak M J. Pharmacodynamics: relation to antimicrobial resistance.  Am J Med. 2006;  119 S37-S44
    PubMedGoogle Scholar
  • 7 Senneville E, Legout L, Valette M et al.. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study.  Clin Ther. 2006;  28 1155-1163
    CrossrefPubMedGoogle Scholar
  • 8 Mader J T, Cantrell J S, Calhoun J. Oral ciprofloxacin therapy compared with standard parenteral therapy for chronic osteomyelitis in adults.  J Bone Joint Surg Am. 1990;  72 104-110
    PubMedGoogle Scholar
  • 9 Kaplan S L, Mason E O, Feigen R D. Clindamycin versus nafcillin or methicillin in the treatment of S. aureus osteomyelitis in children.  South Med J. 1982;  75 138-142
    PubMedGoogle Scholar
  • 10 Tice A D, Hoaglund P A, Shoultz D A. Risk factors and treatment outcomes in osteomyelitis.  J Antimicrob Chemother. 2003;  51 1261-1268
    CrossrefPubMedGoogle Scholar
  • 11 Cremieux A C, Carbon C. Experimental models of bone and prosthetic joint infections.  Clin Infect Dis. 1997;  25 1295-1302
    CrossrefPubMedGoogle Scholar
  • 12 Lazzarini L, Overgaard K A, Conti E, Shirtliff M E. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis?.  J Chemother. 2006;  18 451-460
    PubMedGoogle Scholar
  • 13 Salgado C J, Jamali A A, Mardini S, Buchanan K, Veit B. A model for chronic osteomyelitis using Staphylococcus aureus in goats.  Clin Orthop Relat Res. 2005;  436 246-250
    PubMedGoogle Scholar
  • 14 Lipsky B A, Berendt A R, Deery G H for the Infectious Diseases Society of America et al. IDSA guidelines: diagnosis and treatment of diabetic foot infections.  Clin Infect Dis. 2004;  39 885-910
    CrossrefPubMedGoogle Scholar
  • 15 Esposito S, Leone S, Noviello S. Outpatient parenteral antibiotic therapy for bone and joint infections: an Italian multicenter study.  J Chemother. 2007;  19 417-422
    PubMedGoogle Scholar
  • 16 Carragee E J, Kim D, van der Vlugt T, Vittum D. The clinical use of erythrocyte sedimentation rate in pyogenic vertebral osteomyelitis.  Spine. 1997;  22 2089-2093
    CrossrefPubMedGoogle Scholar
  • 17 Roine I, Faingezicht I, Arguedas A, Herrera J F, Rodríguez F. Serial serum C-reactive protein to monitor recovery from acute hematogenous osteomyelitis in children.  Pediatr Infect Dis J. 1995;  14 40-44
    PubMedGoogle Scholar
  • 18 Bocchini C E, Hulten K G, Mason Jr E O et al.. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children.  Pediatrics. 2006;  117 433-440
    CrossrefPubMedGoogle Scholar
  • 19 Klevens R M, Morrison M A, Nadle J et al.. Invasive methicillin-resistant Staphylococcus aureus infections in the United States.  JAMA. 2007;  298 1763-1771
    CrossrefPubMedGoogle Scholar
  • 20 Guglielmo B J, Luber A D, Paletta Jr D, Jacobs R A. Ceftriaxone therapy for staphylococcal osteomyelitis: a review.  Clin Infect Dis. 2000;  30 205-207
    CrossrefPubMedGoogle Scholar
  • 21 Peltola H, Unkila-Kallio L, Kallio M J. Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group.  Pediatrics. 1997;  99 846-850
    CrossrefPubMedGoogle Scholar
  • 22 Jaberi F M, Shahcheraghi G H, Ahadzadeh M. Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial.  J Pediatr Orthop. 2002;  22 317-320
    CrossrefPubMedGoogle Scholar
  • 23 Norden C W, Fierer J, Bryant R. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin.  Rev Infect Dis. 1983;  5 S495-S501
    PubMedGoogle Scholar
  • 24 Shorr A F. Epidemiology of staphylococcal resistance.  Clin Infect Dis. 2007;  45 S171-S176
    CrossrefPubMedGoogle Scholar
  • 25 Small P M, Chambers H F. Vancomycin for S. aureus endocarditis in intravenous drug users.  Antimicrob Agents Chemother. 1990;  34 1227-1231
    CrossrefPubMedGoogle Scholar
  • 26 Kollef M H. Limitations of vancomycin in the management of resistant staphylococcal infections.  Clin Infect Dis. 2007;  45 S191-S195
    CrossrefPubMedGoogle Scholar
  • 27 Hidayat L K, Hsu D I, Quist R et al.. High-dose vancomycin therapy for methicillin-resistant S. aureus infections: efficacy and toxicity.  Arch Intern Med. 2006;  166 2138-2144
    CrossrefPubMedGoogle Scholar
  • 28 Norden C W, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus.  J Infect Dis. 1986;  153 956-959
    PubMedGoogle Scholar
  • 29 Rodriguez W, Ross S, Khan W, McKay D, Moskowitz P. Clindamycin in the treatment of osteomyelitis in children.  Am J Dis Child. 1977;  131 1088-1093
    PubMedGoogle Scholar
  • 30 Siberry G K, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant S. aureus expressing inducible clindamycin resistance in vitro.  Clin Infect Dis. 2003;  37 1257-1260
    CrossrefPubMedGoogle Scholar
  • 31 Saengnipanthkul S, Pongvivat T, Mahaisavariya B, Laupattarakasem W. Co-trimoxazole in the treatment of chronic osteomyelitis.  J Med Assoc Thai. 1988;  71 186-191
    PubMedGoogle Scholar
  • 32 Markowitz N, Quinn E L, Saravolatz L D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of S. aureus infection.  Ann Intern Med. 1992;  117 390-398
    PubMedGoogle Scholar
  • 33 Atkins B, Gottlieb T. Fusidic acid in bone and joint infections.  Int J Antimicrob Agents. 1999;  12 S79-S93
    CrossrefPubMedGoogle Scholar
  • 34 Rissing J P. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones.  Clin Infect Dis. 1997;  25 1327-1333
    CrossrefPubMedGoogle Scholar
  • 35 Melhus A. Fluoroquinolones and tendon disorders.  Expert Opin Drug Saf. 2005;  4 299-309
    CrossrefPubMedGoogle Scholar
  • 36 Metzler K, Hansen G M, Hedlin P et al.. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant S. aureus. .  Int J Antimicrob Agents. 2004;  24 161-167
    CrossrefPubMedGoogle Scholar
  • 37 Drancourt M, Stein A, Argenson J N et al.. Oral rifampicin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.  Antimicrob Agents Chemother. 1993;  37 1214-1218
    PubMedGoogle Scholar
  • 38 Ruhe J J, Monson T, Bradsher R W, Menon A. Use of long-acting tetracyclines for methicillin-resistant S. aureus infections: case series and review of the literature.  Clin Infect Dis. 2005;  40 1429-1434
    CrossrefPubMedGoogle Scholar
  • 39 Lovering A M, Zhang J, Bannister G C et al.. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.  J Antimicrob Chemother. 2002;  50 73-77
    CrossrefPubMedGoogle Scholar
  • 40 Rayner C R, Baddour L M, Birmingham M C et al.. Linezolid in the treatment of osteomyelitis: results of compassionate use experience.  Infection. 2004;  32 8-14
    CrossrefPubMedGoogle Scholar
  • 41 Falagas M E, Siempos I I, Papagelopoulos P J, Vardakas K Z. Linezolid for the treatment of adults with bone and joint infections.  Int J Antimicrob Agents. 2007;  29 233-239
    CrossrefPubMedGoogle Scholar
  • 42 Rao N, Ziran B H, Wagener M M, Santa E R, Yu V L. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections.  Clin Infect Dis. 2004;  38 1058-1064
    CrossrefPubMedGoogle Scholar
  • 43 Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval.  Pharmacology. 2007;  81 79-91
    PubMedGoogle Scholar
  • 44 Lamp K C, Friedrich L V, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis.  Am J Med. 2007;  120 S13-S20
    PubMedGoogle Scholar
  • 45 Yin L Y, Lazzarini L, Li F, Stevens C M, Calhoun J H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.  J Antimicrob Chemother. 2005;  55 995-1002
    CrossrefPubMedGoogle Scholar
  • 46 Zimmerli W, Widmer A F, Blatter M, Frei R, Ochsner P E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.  JAMA. 1998;  20 1537-1541
    PubMedGoogle Scholar
  • 47 Mulleman D, Philippe P, Senneville E et al.. Streptococcal and enterococcal spondylodiscitis (vertebral osteomyelitis). High incidence of infective endocarditis in 50 cases.  J Rheumatol. 2006;  33 91-97
    PubMedGoogle Scholar
  • 48 Rice L B. Antimicrobial resistance in gram-positive bacteria.  Am J Infect Control. 2006;  34 S11-S19
    CrossrefPubMedGoogle Scholar
  • 49 Graham A C, Mercier R C, Achusim L E, Pai M P. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.  Ann Pharmacother. 2004;  38 936-941
    CrossrefPubMedGoogle Scholar
  • 50 Leibovitz E. The use of fluoroquinolones in children.  Curr Opin Pediatr. 2006;  18 64-70
    PubMedGoogle Scholar
  • 51 Bodi M, Garnacho J. Pseudomonas aeruginosa: combined treatment vs. monotherapy.  Med Intensiva. 2007;  31 83-87
    PubMedGoogle Scholar
  • 52 Tascini C, Gemignani G, Palumbo F et al.. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant P. aeruginosa diabetic foot infections with or without osteomyelitis.  J Chemother. 2006;  18 648-651
    PubMedGoogle Scholar
  • 53 American Thoracic Society, CDC, and Infectious Diseases Society of America . Treatment of tuberculosis.  Am J Respir Crit Care Med. 2003;  167 603-662
    CrossrefPubMedGoogle Scholar
  • 54 American Thoracic Society and Infectious Diseases Society of America . ATS/IDSA statement: diagnosis, prevention and treatment of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
    CrossrefPubMedGoogle Scholar
  • 55 Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis.  N Engl J Med. 2005;  352 2325-2336
    CrossrefPubMedGoogle Scholar
  • 56 Robinson J L, Vaudry W L, Dobrovolsky W. Actinomycosis presenting as osteomyelitis in the pediatric population.  Pediatr Infect Dis J. 2005;  24 365-369
    PubMedGoogle Scholar

Henry S FraimowM.D. 

Division of Infectious Diseases, Cooper University Hospital

401 Haddon Avenue, Room 274, Camden, NJ 08103

Email: fraimow-henry@cooperhealth.edu

      >